J&J’s JJDC Venture Arm Co-Leads Delix Therapeutics’ $100 Million Round

Delix Therapeutics has raised $100 million in a Series C led by Johnson & Johnson’s venture investment arm and SV Health Investors’ Dementia Discovery Fund, funding further clinical work on its depression candidate.

Delix closed the financing Nov. 9. Its co-lead investors were Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson’s venture capital organization, and SV Health Investors’ Dementia Discovery Fund.

The proceeds will support Zalsupindole’s development through Phase IIb proof-of-concept testing for recurrent major depressive disorder and advance other candidates in Delix’s neuroplastogen pipeline.

Zalsupindole is an oral drug inspired by psychedelics and designed to promote neuroplasticity without hallucinatory effects. Delix expects to start a Phase II trial of the drug in the first half of 2027.